Apolipoprotein E and Alzheimer's Disease: Ethnic Variation in Genotypic Risks by Maestre, Gladys et al.
Apolipoprotein E and Alzheimer's Disease: 
Ethnic Variation in Genotypic Rsks 
Gladys Maestre, MD,$"" Ruth Ottman, PhD,*tiS Yaakov Stern, PhD,* $'?t Barry Gurland, MD,$$ 
Michael Chun, MD,' Ming-Xin Tang, PhD,"' Michael Shelanski, MD,  PhD,$*" 
Benjamin Tycko, MD,  PhD,SX* and Richard Mayeux, MD,  MSE*tSntfi 
The presence of the apolipoprotein E4 (apo € 4 )  allele significantly increases the risk of Alzheimer's disease. Whether 
this is due to biological effects of the apo E4 protein or reflects linkage disequilibrium with an as yet unidentified 
Alzheimer's disease susceptibility gene is of critical importance. In a community study in northern Manhattan we found 
a fivefold increase in the risk of Alzheimer's disease among African-Americans, Hispanics, and whites homozygous for 
apo ~ 4 .  Overall, the risk between Alzheimer's disease and apo ~4 heterozygosity was also increased by twofold, but 
the association was somewhat weaker for African-Americans than for Hispanics and whites. In  contrast, the apo e 2 / ~ 3  
genotype was associated with an eightfold increased risk of Alzheimer's disease in African-Americans but it was 
associated with reduced risk in whites. Variability in the strength and type of association between Alzheimer's disease 
and the apo E polymorphisms in the three ethnic groups could not be fully explained by age differences. The allelic 
frequency of apoe"4 was significantly higher in patients than control subjects in all ethnic groups at age 70 or younger, 
reflecting the higher proportion of apo E4 homozygotes, but this difference diminished with increasing age. The  
allelic frequency of apoe'2 for African-Americans and Hispanics, but not whites, was significantly higher in patients 
than control subjects, but only after age 70. Though these findings need confirmation, they suggest that modifier 
genes or environmenral factors may interact selectively with apo E4 in African-Americans to weaken the association 
with Alzheimer's disease or that the apo E allelic system is in linkage disequilibrium with a nearby, as yet unidentified 
Alzheimer's disease susceptibility locus. 
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Among the three common polymorphisms of apolipo- 
protein (apo) E, ~ 2 ,  t - 3 , and ~ 4 ,  the prevalence of the 
~4 allele has been found to be increased among white 
patients with Alzheimer's disease (AD)  compared to 
healthy control subjects 11-81, while the presence of 
an apo t-2 allele may provide protection 191. Both the 
increased risk of A D  associated with apo ~4 and the 
decreased risk associated with apo e2 may diminish 
with age, however [7 ] .  Because the genetic locus for 
apo E is on chromosome 19 within the region linked 
to late-onset familial AD 1101 and because of the con- 
sistent association of A D  with apo t-4 in both familial 
and sporadic disease, it has been proposed that the 
presence of one or more apo FA alleles increases sus- 
ceptibility to AD. While arguments for a direct effect 
of a particular allelic variant of the apo E protein on 
the neuronal pathology have been made i l l ,  the in- 
creased risk of A D  conferred by apo ~4 might alterna- 
tively reflect linkage disequilibrium with a nearby A D  
susceptibility gene. 
The association between apo €4  and A D  has been 
examined primarily in white populations from the 
United States and Europe. However, apo E has been 
extensively investigated in populations worldwide be- 
cause of its role in lipid metabolism and ischemic car- 
diovascular disease [ 1 13. The  highest frequency of apo 
€4 occurs among Finns, Icelandics, Sudanese, Nigeri- 
ans, and African-Americans [ 12, 131. Preliminary data 
from our community-based study 183 suggested that 
apo ~4 was not associated with AD among African- 
Americans. In that small study, the degree of asso- 
ciation between apo €4 and A D  among Hispanics 
appeared to be intermediate between that in 
African-Americans and that in whites, consistent with 
the known African admixture in Hispanics of Carib- 
bean origin [ 141. The  lack of a clear association be- 
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tween AD and apo ~4 among African-Americans raised 
the possibility that apo a4 might be in linkage disequi- 
librium with another  AD susceptibility locus, or alter- 
natively, that African-Americans might have a modifier 
gene  (or genes) or environmental exposures that alter 
the  biological effect of apo a4. With this background, 
w e  conducted a larger case-control study based in the  
same community t o  test the hypothesis that the  associa- 
tion of A D  with the apo E allelic system differs among 
African-Americans, whites, and Hispanics. 
Materials and M e t h o d s  
Subjects and Setting 
Patients were identified from a community-based dementia 
registry from a number of sources: regional hospitals (includ- 
ing inpatient and outpatient services), private practitioners 
in the community, federal and state health agencies, health 
maintenance organizations. and senior centers. Control sub- 
jects were recruited from the same source as patients and 
received identical interviews and clinical assessments (de- 
scribed below), which included a structured interview of fam- 
ily history. The refusal rate for both case patients and control 
subjects was less than 20?+ using the registry. We previously 
reported the development of our diagnostic methods and its 
relationship to the cultural and educational demographics of 
this community 115, 161. None of the control subjects were 
spouses or relatives of case patients. 
Diagnoszs 
A physician elicited the medical and neurological history and 
conducted a standardized physical and neurological examina- 
tion. All ancillary information, including medical charts and 
reports of laboratory studies, were included in the evaluation, 
but data regarding apo E genotypes were shielded from the 
clinical diagnostic process. A standardized neuropsychologi- 
cal battery that measured performance in memory, orienta- 
tion, abstract reasoning, language, and construction and mea- 
surement of activities of daily living was used to determine 
whether subjects met the cognitive and functional criteria for 
dementia. All clinical information was reviewed at a diagnos- 
tic conference of physicians and neuropsychologists to arrive 
at consensus diagnosis. The diagnosis of AD was based on 
criteria from the Diagnostic and Statijticill Manual of Mental 
Disovdevs. 3rd edition-revised [17], and the National Insti- 
tute of Neurological and Communicative Disorders and 
Srroke- Alzheimer’s Disease and Related Disorders Associa- 
tion [181. The majority of patients were alive at the time of 
this investigation, but data were also available on 16 patients 
with postmortem confirmation of diagnoses identified in the 
same registry. 
Family Hkto y Assessment 
A structured family history interview for AD and other neu- 
rological disorders in first-degree relatives (parents and full 
siblings) was obtained. An initial screening question when 
answered affirmatively triggered a set of follow-up questions 
designed to ascertain historical information necessary for di- 
agnosis. Operational criteria were then applied ro the answers 
to the follow-up questions, to arrive at a diagnosis that was 
scaled according to the degree of certainty. The categories 
“dehnite,” “probable,” “possible,” and “uncertain” required 
more than one affirmative response to the symptoms. The 
“doubtful” category was reserved for relatives with an affir- 
mative response to the screening question but a negative 
response to all other symptoms. “Unknown” was reserved 
for family members where no information was available (i.e., 
an “unknown” response to the screening question). The reli- 
ability of this interview has been reported [19]. 
Ethnic Group 
For ethnic group classification, we used the format suggested 
by the 1990 US Census Bureau [20]. The 1990 census allows 
for the identification of Hispanics as a cultural group with 
further designation of African-American or black, white, and 
other. We separated subjects into three ethnic groups ac- 
cording to self-report: African-American, Hispanic, and 
white (non-Hispanic), based on direct interview with the sub- 
jects or a family member. 
Geriomir D N A  Aniplification atzd 
Rrstvirtiori lsotyping of Apo E 
Genomic DNA was amplified by polymerase chain reaction 
(PCR), using reaction conditions modified from those de- 
scribed by Hixson and Vernier 121). Briefly, each amplifica- 
tion contained 200 ng of genomic DNA, 25 pmol of each 
primer [2l], 10% dimethyl sulfoxide, and 0.5 unit of Tag 
D N A  polymerase (Boehringer Mannheim) in a final volume 
of 25 ~ 1 .  Initial denaturation was at 94°C for 5 minutes, 
followed by 40 cycles of annealing at 65°C for 30 seconds, 
extension at 72°C for 30 seconds, denaturation at 94°C for 
1 minute. followed by a final extension at 72°C for 10 min- 
utes. The amplification product (10 ~ 1 )  was then digested 
with 10 units of Cfol (Boehringer Mannheim) for 3 hours at 
37°C and electrophoresed for 15 hours at 300 V through a 
20‘T polyacrylamide gel. The genotypes were determined by 
the sizes of DNA fragments present, viewed, and photo- 
graphed under ultraviolet light after staining with 0.5 WgLml 
of ethidium bromide. All genotypes were determined with- 
out  knowledge of patient-control status. 
Data Analysis 
Allele frequencies for patients with AD and control subjects 
were determined by counting alleles and calculating sample 
proportions. Frequencies of apo E genotypes in patients and 
control subjects were compared using the x 2  test and the 
approximate test based on the normal approximation to the 
binomial distribution [22). We estimated both simple and 
stratified (by ethnic group) odds ratios (ORs) [22] for AD 
associated with the presence of the apo € 4  and ~2 alleles 
(homozygous and heterozygous), using subjects with the apo 
€3183  genotype as the reference group. The frequencies for 
the demographic categories, including ethnic groups, were 
compared among case patients and control subjects using x L  
analyses and Fisher’s exact tests 122). Tests for homogeneity 
[ZZ) were also used to measure the degree of variability 
across the ethnic groups. This statistic has a x’ distribution 
under the null hypothesis of a consistent (homogeneous) as- 
sociation. Thus, the value of x is increased when groups are 
inhomogeneous. Both univariate and multivariate ORs for 
AD associated with apo €4 and ~2 were also calculated from 
logistic regression [ 2 3 ] ,  adjusting for age and ethnic group. 
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Results 
Characteristics o f  Stud31 Population 
Data from 145 patients with A D  and 206 healthy el- 
derly unrelated control subjects were ascertained. Pa- 
tients and control subjects did not differ by gender 
(AD: 37.2% men; controls: 42.29 men). In all ethnic 
groups combined, patients were slightly older (75.3 k 
10.5 [range, 46-76] years) than control subjects (72.5 
'-+ 7.8 [range, 46-73] years, p < 0.05). Also African- 
American and Hispanic subjects were older than Cau- 
casians (Table l). Patients also had less education (AD: 
8.2 2 5.6 years; controls: 7.4 +- 4.7 years; p < 0.05) 
than did control subjects. 
Apo E Allelic Frequencies and Genotypes 
There was a significant difference in the distribution of 
apo E alleles among the three ethnic groups within the 
control group (x' = 17.5, 4df. p < 0.001, see Table 
1 ) .  The apo ~4 allele frequency was higher in African- 
American than in Hispanic or white control subjects, 
and both African-Americans and Hispanics had a lower 
frequency of apo ~2 than did white control subjects. 
The genotype distributions for control subjects within 
each ethnic group were in Hardy-Weinberg equilib- 
rium (Table 2). Among patients the distribution of apo 
E alleles also differed across ethnic groups (x' = 7.5, 
df4,  p = 0.051, with higher frequencies of both apo 
~4 and e2 in African-Americans than in the other two 
ethnic groups. Among patients, neither a family history 
of dementia in a first-degree relative nor a history of 
onset of A D  after age 65 was related to any apo E 
genotype. 
Meaurres of Association: Odds Ratios 
Combining all three ethnic groups, the OR adjusted 
for age and ethnic group for AD associated with horno- 
zygosity for apo ~4 was 5.1 ( 9 5 T  confidence interval 
[CI]: 1.7-15.0;p < 0.005) and that for heterozygosity 
was 2.1 (959  CI: 1.2-3.2; p < 0.005). Within each 
ethnic group, we estimated the OR for AD associated 
with each individual apo E genotype (see Table 2) .  
There was a strong association between AD and apo 
Table I .  Distributiorij o/ Apo E Grtiotypej among Patients with Alzheinier's Disease and Control Snbjerts by Ethnzc Gror4p.r" 
Ethnic G r o u p s  N Age (yr) Apo'~3 Apo*e4 Apo'd 
African-American 
Alzheimer's disease 41 76 (8.8) 0.56 
Control 57 74 (5 .@ 0.74 
Hispanic 
Alzheimer's disease 61 76 (9.4) 0.70 
Control 90 74 (7. lP 0.84 
Alzheimer's disease 43 71 (9.9) 0.7 1 
















'Allelic frequencies differed significantly between case patients and control subjects within and across ethnic groups. See text for explanation, 
bSignificant difference within each stratum ( p  < 0.05). 
Table 2. Odds Ratios for Alzheimer's Disease Associated with Apo E Genotype by Ethnic Group" 
Ethnic G r o u p s  E 3 i E 3  €21~3 E2/E2 E41E.2 E31E4 E4/E4 
African-American 
Alzheimer's disease 12 7 1 1 15 5 
Control 30 2 0 0 23 2 
Odds ratio 1.0 reference 8.8 (1.6-48.0)b ' 
Alzheimer's disease 33 2 1 3 18 4 
Control 65 5 0 0 18 2 
Odds ratio 1.0 reference 0.8 (0.2-4.3) 
Alzheimer's disease 22 1 0 1 16 3 
Control 42 8 0 1 7 1 
Odds ratio 1.0 reference 0.2 (0.03-2.00) 1.9 (0.1-32.0) 4.4 (1.6-12.2)b 5.7 (0.6-58.0) 
C 1.6 (0.6-4.2) 8.2 (1.3-51.0)b 
Hispanic N 
C 2.0 (0.9-4.5) 4.2 (0.7-24.0) 
White N 
"All odds ratio estimates were computed and age adjusted by logistic regression The numbers in parentheses indicate the 95C: confidence 
interval tor the odds ratio The expected frequencies, given Hardy-Weinberg equilibrium, are provided for controls in each ethnic group 
African-American-F3/F~ (5557), E 3 / E 4  (33'4). ~ 3 / ~ 2  (3%), L 4 / E 4  (69t1, ~ 4 1 ~ 2  ( 
E ~ / E Z  (>';), F4/F4 ( Z c { ) ,  E3/E2 ( 8c-0, E2/F2 (2$;).white-E3/E3 (7oT). E3/F4 (15%),  E3/E2 (12%), P4/E4 
E2/F2 ( 5 3 ) ,  Hispanic-Fi/Fi ( 'or<), t3/F4 ( ? L r < ) ,  
), €4/€2 (1  5';). F2/c2 ( 
hStatistical significance, p < 0 0 1  for each 
'Odds ratio was not calculdrecl because of an empty cell 
'No pdricnts or control tubjecrs were tound with this genotype 
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e4/e4 in all three ethnic groups. The OR for apo e 3 / ~ 4  
appeared to be stronger in whites (4.4) than in African- 
Americans (1.6) or Hispanics (2.0), although the statis- 
tical test for heterogeneity of this association did not 
demonstrate significance ( x h  = 2.2, 2df; p > 0.05). 
There was a positive association berween A D  and apo 
~ 2 / e 3  in African-Americans (OR = 8.8), and a nega- 
tive association with this genotype in the other two 
ethnic groups (see Table 2: Hispanics, 0.8; whites, 0.2); 
this difference was statistically significant (xh = 8.9, 
Because the associations between A D  and both apo 
.52 and apo e4 have been reported to vary with age 
[9], we performed two further analyses. First, we inves- 
tigated the possibility that the age differences across 
the three ethnic groups explained the weaker associa- 
tion berwcen the apo e 4 / ~ 3  genotype and AD in Afri- 
can-Americans compared to that in Hispanics and 
whites. For this purpose we excluded patients and con- 
trol subjects below the age of 65 and above the age of 
85, thus eliminating the age differences among the 
three ethnic groups (African-Americans, 74.3 k 5.4; 
Hispanics, 73.9 k 5.2; whites, 74.7 ? 5.4; F = 1.4, 
p > 0.05). We then reestimated the OR associated 
with apo .54/e3 and apo e 2 / ~ 3  using logistic regression 
to adjust for any residual age differences between pa- 
tients and control subjects. The results of this analysis 
were very similar to those shown in Table 2. The OR 
for apo e 4 / e 3  was 1.5 (95Ti' CI: 0.5-4.7) in Afri- 
can-Americans, 2.6 (95% CI: 1.0-6.4) in Hispanics, 
and 3.9 (9576 CI: 1.2-12.6) in whites. The OR for 
apo e2/e3 was 18.8 (95% CI: 4.7-74.8) in African- 
Americans, 0.6 (75% CI: 0.4-10.6) in Hispanics, and 
0.2 ( 9 5 q  CI: 0.0-8.6) in whites. 
Second, to clarify further the effect of age on the 
relationship between A D  and apo E, we compared the 
allelic frequencies for apoe+2, e*3, and .5*4 among pa- 
tients and control subjects in all three ethnic groups 
across three age strata: age 70 and younger, age 71 to 
80, and age 81 and older (Fig). At age 70 and younger, 
the allelic frequency for apo e4 was significantly ele- 
vated among patients compared with control subjects 
in all three ethnic groups, possibly reflecting the higher 
frequency of apo e4 homozygosity (6.5 vs 1.2%). In 
African-Americans and whites, the apoe*4 frequency 
in patients diminished with increasing age; this pattern 
was not apparent in Hispanics. In African-American 
control subjects, the apoe'4 frequency was higher 
among subjects over age 70 than among those age 70 
or younger. The apos"2 allelic frequency also differed 
over the three age groups. In African-Americans and 
Hispanics, the frequency of apoe"2 was significantly 
increased among patients compared with control sub- 
jects in the older age groups (see Fig; African- 
Americans age 71 and older: A D  15% vs controls 
l.l$?, z = 2.7, p < 0.01; and Hispanics age 71  and 
older: A D  7.1%, vs controls 0.9$6, z = 2.3,p < 0.02). 
2df; p < 0.05). 
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70 & younger 71 to 80 yrs. 81 & older 
Frequencies for the three comnion upoftpoprotein E affefes in pa- 
tientA u,ith Alzheimerls disease (AD) and a group of elderly CON- 
trof subjectJ- from a ronimunity in northern Manhattan. Solid 
bars indicate patients uith A D  while the cross-hatched bars 
indicate controls. Ethnic groups are diimided and identifed in  
tbe upper left corner ofearh box and the groupJ are further sub- 
d i d e d  into three age strata based on the distribution of subjects 
oimeralf (570.  71-80, and 281).  Patients with AD had a j ig-  
n$c.anti'y higher frequenry of apo~"4 in all three ethnic groupJ. 
but on/$ in the louwt age .rtratum. I n  ivvtrast. African- 
American and Hi.cpanic patietits umith A D  had .rignificanti$ 
higher frequencies of apoP2, but the number ofs/rbjects uitb 
this allele was relatii~ely snuff .  
Among whites the frequency of apoe*2 was higher in 
control subjects than in patients in all age groups. 
Discussion 
Our findings indicate a uniform increased risk of A D  
among African-Americans, whites, and Hispanics ho- 
mozygous for apo ~ 4 .  Apo e4 heterozygosity was also 
associated with an increased risk of AD, but this associ- 
ation was somewhat weaker in African-Americans than 
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in the other two ethnic groups. The risk of AD was 
also increased for African-Americans with an apo ~2 
allele, whereas it was decreased for whites with this 
polymorphism, as previously reported by Corder and 
coauthors [9]. These differences do not appear to be 
due to any disparity in age across the three ethnic 
groups because the ORs were virtually unchanged in 
the analysis involving subjects of comparable age. 
However, the results are based on a small number of 
subjects in each ethnic group and require confirmation. 
Nevertheless, there are at least three possible explana- 
tions for these results, each of which suggest new lines 
of inquiry into the complex genetics of AD. 
First, it is possible that apo ~4 has a direct effect 
on A D  susceptibility, but that African-Americans have 
either a modifier gene (or genes) or environmental ex- 
posures that “partially” protect them from the effects 
of the apo e4 protein. Modifier genes or exposures 
might alter the effects of a single apo ~4 allele, but not 
the higher gene dose with two apo ~4 alleles. Thus, 
apo ~4 homotygosity was unequivocally associated 
with increased risk, while the effect of a single apo ~4 
allele was not. T o  account for the positive association 
between AD and apo e2 in African-Americans and the 
negative association between A D  and apo FZ in whites, 
however, this direct effect model would also require 
that there be inodiher genes or risk factors affecting 
both apo e4 and apo r2,  and in opposite directions. 
Studies to identify genes or exposures that modify the 
effects of the apo E proteins will be critical. 
The frequency of apo e4 was higher among African- 
American control subjects than in control subjects 
from the other ethnic groups. A prevalence study 1241 
in this community found rates of dementia to be identi- 
cal in the three ethnic groups. While the specific types 
of dementia were not described, preliminary analyses 
indicate no significant difference in the prevalence of 
AD by ethnic group 1251. Studies to determine 
whether other populations [ 123 with high frequencies 
of the apo e4 allele manifest a relative excess of late- 
onset A D  compared to those with lower apo e4 fre- 
quencies would be important. 
A second explanation for the different allelic associa- 
tions of apo E with A D  among African-Americans and 
whites is that the associations are due to linkage dis- 
equilibrium, rather than to a direct effect of apo ~ 4 .  
An A D  susceptibility gene may be in linkage disequi- 
librium with apo e4 in whites and with apo ~4 and 
~2 in African-Americans. According to this model, the 
allelic variants at the putative A D  susceptibility locus 
must have arisen early in the diversification of racial 
groups. Clearly, if apo 64 is not itself the A D  suscepti- 
bility gene but instead is in linkage disequilibrium with 
this gene, then studies to identify the true A D  suscepti- 
bility locus should focus on other genes tightly linked 
to apo E. 
Corder and coauthors [9] suggested that the inde- 
pendent, negative association with apo FZ in whites 
provided evidence against linkage disequilibrium, be- 
cause it would require association of apo ~4 with an 
allele increasing susceptibility to AD, and association 
of apo ~2 with an allele decreasing susceptibility to 
AD. We suggest an alternative explanation for the data 
in whites: An A D  susceptibility allele may be in linkage 
disequilibrium both with apo ~4 and to a lesser extent, 
with apo ~ 3 .  This would also account for the lower risk 
in whites with apo ~2 than in those with either apo ~3 
or apo ~ 4 ,  and would be consistent with the different 
allelic associations in African-Americans. 
The third possibility is that ethnic differences in the 
associations between A D  and apo ~4 observed in this 
community study are due to differential survival among 
older patients with an apo €4 allele. Our results indi- 
cate that the apo e4 allelic frequency in patients dimin- 
ishes with age. In whites, the apo ~4 allelic frequency 
in control subjects remained unchanged with age 
(= 1 O%), whereas in African-Americans it increased 
with advancing age (=25Tt’). This was not expected 
because the presence of an apo e4 allele has been asso- 
ciated with increased risk of coronary artery disease, 
particularly that associated with mortality [26]. This 
may be due simply to the small number of African- 
Americans in this study who were 70 years or youn- 
ger, but the allelic frequency in the older African- 
Americans is similar to that previously reported [ 12, 
131. Alternately, other genetic or environmental fac- 
tors may contribute to the differences in lipid metabo- 
lism related to apo E and the association with heart 
disease 127, 28). Prospective studies will be essential 
to clarify the relationship between apo ~4 and survival 
in the presence and absence of AD. 
At least two hypotheses that implicate apo E in the 
etiology of A D  have been advanced. Strittmatter and 
colleagues 11, 291 proposed apo E as a P-amyloid se- 
questering agent. Consistent with this position are the 
observations that apo E colocalizes with P-amyloid and 
that the degree of binding in vitro is greatest with the 
apo e4 protein (homozygous > heterozygous). An- 
other hypothesis forwarded by chis group proposes 
that the absence of apo e3 results in more rapid 7 
phosphorylation, leading to instability of the microtu- 
bule system in neurons and the formation of paired 
helical filaments and neurofibrillary tangles in A D  [30]. 
The current findings of an association between A D  and 
both apo e4 and €2 in African-Americans are perhaps 
more consistent with this hypothesis. 
Uncovering a marker of genetic susceptibility to AD 
is of major public health importance because the dis- 
ease is both common and costly. Given the variable 
prevalence of the major polymorphisms of apo E, it is 
possible that other populations may also differ with 
regard to the association between A D  and apo E. The 
predictive value of a test for risk, however defined, will 
vary with the prevalence of A D  and with the frequen- 
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cies of apo E polymorphisms in the population 1221. 
Published data to date imply that a test based on the 
apo E allele system might accurately assess A D  risk in 
some populations. While this may be true, caution is 
warranted because data from populations with higher 
known frequencies of apo ~4 have not been thoroughly 
investigated with regard to the association with AD. 
As with any test for disease risk, individuals are likely 
to make important decisions concerning their lives 
based on the perception that they (or their family 
members) carry the disease gene or are at increased 
risk of developing the disease. Our data suggest that 
commercial initiatives to exploit apo E allelic analysis 
as an assessment of the risk of A D  may be premature. 
Nevertheless, several lines of research are now open. 
A thorough analysis of D N A  near the apo E locus for 
additional transcription units should be undertaken as 
well as a search for additional susceptibility or modifier 
loci and potential environmental factors in populations 
with higher apo e4 allelic frequencies to identify factors 
or genes that modify the effect of an A D  susceptibility 
gene. 
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